Mechanisms of disease: Genetics of Paget’s disease of bone and related disorders

University of Edinburgh, UK.
Nature Clinical Practice Rheumatology (Impact Factor: 5.85). 06/2006; 2(5):270-7. DOI: 10.1038/ncprheum0172
Source: PubMed


Paget's disease of bone (PDB) is a common disorder in which focal abnormalities of increased bone turnover lead to complications such as bone pain, deformity, pathological fractures, and deafness. PDB has a strong genetic component and several susceptibility loci for the disease have been identified by genome-wide scans. Mutations that predispose individuals to PDB and related disorders have been identified in four genes. The rare PDB-like syndromes of familial expansile osteolysis, early-onset familial PDB, and expansile skeletal hyperphosphatasia are caused by insertion mutations in TNFRSF11A, which encodes receptor activator of nuclear factor (NF)kappaB (RANK)-a critical regulator of osteoclast function. Inactivating mutations in TNFRSF11B, which encodes osteoprotegerin (a decoy receptor for RANK ligand) cause idiopathic hyperphosphatasia, and polymorphisms in this gene seem to increase the risk for classical PDB. Mutations of the sequestosome 1 gene (SQSTM1), which encodes an important scaffold protein in the NFkappaB pathway, are a common cause of classical PDB. The rare syndrome of hereditary inclusion body myopathy, PDB, and fronto-temporal dementia is caused by mutations in the valosin-containing protein (VCP) gene. This gene encodes VCP, which has a role in targeting the inhibitor of NFkappaB for degradation by the proteasome. Several additional genes for PDB remain to be discovered, and it seems likely that they will also involve the RANK-NFkappaB signaling pathway or components of the proteasomal processing of this pathway, underscoring the critical importance of this signaling pathway in bone metabolism and bone disease.

1 Follower
7 Reads
  • Source
    • "Altered expression of OPG has been described in a variety of human diseases that are associated not only with skeletal abnormalities, but also with hearing loss of poorly understood etiology. Loss of function mutations in the OPG gene account for the majority of cases of Juvenile Paget's disease (Daroszewska and Ralston, 2006; Whyte et al, 2002), an autosomal recessive osteopathy characterized by a generalized increase in bone turnover leading to widespread skeletal deformities in childhood , bone pain and deafness. Genetic variation at the OPG locus is a risk factor for adult-onset Paget's disease (Daroszewska et al., 2004) and osteoporosis (Richards et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoprotegerin (OPG) is a key regulator of bone remodeling. Mutations and variations in the OPG gene cause many human diseases that are characterized by not only skeletal abnormalities but also poorly understood hearing loss: Paget's disease, osteoporosis, and celiac disease. To gain insight into mechanisms of hearing loss in OPG deficiency, we studied OPG knockout (Opg (-/-)) mice. We show that they develop sensorineural hearing loss, in addition to conductive hearing loss due to abnormal middle-ear bones. OPG deficiency caused demyelination and degeneration of the cochlear nerve in vivo. It also activated ERK, sensitized spiral ganglion cells (SGC) to apoptosis, and inhibited proliferation and survival of cochlear stem cells in vitro, which could be rescued by treatment with exogenous OPG, an ERK inhibitor, or bisphosphonate. Our results demonstrate a novel role for OPG in the regulation of SGC survival, and suggest a mechanism for sensorineural hearing loss in OPG deficiency.
    Full-text · Article · Apr 2013 · Neurobiology of Disease
  • Source
    • "Interestingly, the causative mutations in VCP all affect the highly conserved CDC 48 domain, which is involved in ubiquitin-binding [Dai and Li, 2001; Rape et al., 2001]. The PDB-causing mutations in the SQSTM1 gene also affect the ubiquitin-binding domain of the gene product, p62 [Layfield and Hocking, 2004], suggesting that the disease processes in PDB associated with SQSTM1 and IBMPFD may be related [Daroszewska and Ralston, 2006]. We believe that IBMPFD is currently underdiagnosed among the patients with myopathy and/or dementia. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inclusion body myopathy with Paget disease of the bone (PDB) and/or frontotemporal dementia (IBMPFD, OMIM 167320), is a progressive autosomal dominant disorder caused by mutations in the Valousin-containing protein (VCP, p97 or CDC48) gene. IBMPFD can be difficult to diagnose. We assembled data on a large set of families to illustrate the number and type of misdiagnoses that occurred. Clinical analysis of 49 affected individuals in nine families indicated that 42 (87%) of individuals had muscle disease. The majority were erroneously diagnosed with limb girdle muscular dystrophy (LGMD), facioscapular muscular dystrophy, peroneal muscular dystrophy, late adult onset distal myopathy, spinal muscular atrophy, scapuloperoneal muscular dystrophy, or amyotrophic lateral sclerosis (ALS) among others. Muscle biopsies showed rimmed vacuoles characteristic of an inclusion body myopathy in 7 of 18 patients (39%), however, inclusion body myopathy was correctly diagnosed among individuals in only families 5 and 15. Frontotemporal dementia (FTD) was diagnosed in 13 individuals (27%) at a mean age of 57 years (range 48.9-60.2 years); however, several individuals had been diagnosed with Alzheimer disease. Histopathological examination of brains of three affected individuals revealed a pattern of ubiquitin positive neuronal intranuclear inclusions and dystrophic neurites. These families expand the clinical phenotype in IBMPFD, a complex disorder caused by mutations in VCP. The presence of PDB in 28 (57%) individuals suggests that measuring serum alkaline phosphatase (ALP) activity may be a useful screen for IBMPFD in patients with myopathy.
    Full-text · Article · Mar 2008 · American Journal of Medical Genetics Part A
  • Source

    Preview · Article ·
Show more